Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Director
Telephone: 412-586-9777
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

University of Pittsburgh's Department of Emergency Medicine to Test Effectiveness of Mechanical Chest Compression Device

Notice of public disclosure for emergency medicine research 

PITTSBURGH, June 9, 2004 As part of an international study, researchers in the department of emergency medicine at the University of Pittsburgh School of Medicine will test the effectiveness of a mechanical chest compression device to see if it does a better job than manual chest compressions for the treatment of out-of-hospital sudden cardiac arrest.

The University of Pittsburgh is one of five centers participating in the AutoPulse Assisted Prehospital International Resuscitation (ASPIRE) Trial to evaluate the safety and effectiveness of AutoPulse, developed by Revivant Corporation of Sunnyvale, Calif.

The AutoPulse Resuscitation System is a U.S. Food and Drug Administration approved external device that is portable and designed to provide consistent automated chest compressions during cardiopulmonary resuscitation (CPR). The device resembles a small surfboard, and patients in cardiac arrest are placed on it and strapped to the board at the chest. The operator then pushes a button to begin the compressions. The AutoPulse is designed to generate chest compression cycles that produce a palpable pulse. During earlier human studies, the AutoPulse generated blood flow to the heart, which was nearly 125 percent of that generated by conventional CPR. Because of the optimal circulatory pressure, AutoPulse also has the potential to improve the circulation of drugs.

Sudden cardiac arrest is the sudden loss of heart function. The mortality rate is more than 90 percent and death usually occurs within minutes unless CPR and rapid defibrillation is available. Despite many advances in medical care, there has not been a significant improvement in the survival rate of cardiac arrest in 30 years.

With poor survival statistics like this, it is important to find alternative methods to combat sudden cardiac arrest, which claims more than 350,000 lives each year, said Vincent N. Mosesso, Jr., M.D., associate professor of emergency medicine at the University of Pittsburgh, medical director of the University of Pittsburgh National Center for Early Defibrillation and principal investigator of the Pittsburgh study.

Observations in the prehospital setting have found that maintaining manual chest compressions is one of the more difficult tasks for a variety of reasons. Additionally, observations in the laboratory with trained paramedics show that the depth of compressions and compression rate diminish rapidly with time from the onset of CPR without the participant being aware of his/her decreased effort.

Because this study could affect anyone living in areas served by the participating EMS agencies, both the university and the researchers are seeking comments from the public. To explain the research and answer questions, the Pitt researchers will hold public forums in the participating communities.

According to federal law and university policy, those who participate in a clinical research study must provide informed consent. Because of the nature of this trial, it is impossible to obtain consent at the time of cardiac arrest. For this reason, the researchers are notifying the public that informed consent will be waived. Researchers will make every attempt to be in contact with family members and, if possible, the cardiac arrest patient to provide notification and obtain consent for continued participation as soon as possible after subject enrollment.

The Pitt researchers will work with seven local emergency service (EMS) agencies to train paramedics on how to use the AutoPulse. During the one-year study, half of the patients will receive manual chest compressions and the other half will receive compressions with the AutoPulse. Patients who survive and agree to continue to participate in the study will be followed for three months after the event. At the conclusion of the study, the researchers will compare the two methods to see which group of patients had a better outcome.

Other cities participating in the ASPIRE Trial include Seattle (the coordinating center with Al Hallstrom, Ph.D., as principal investigator and professor of biostatistics at the University of Washington); Calgary, Alberta; Vancouver, British Columbia and Columbus, Ohio. With all of the centers combined, the researchers hope to enroll 2,300 patients. The Pittsburgh researchers hope to enroll 500 patients locally.

The seven EMS agencies participating in the ASPIRE Trial include Baldwin EMS, Tri-Community South EMS, Medical Rescue Team South, Northwest EMS, McKeesport Area EMS, Eastern Area Prehospital Services and Ross/West View EMS.

The department of emergency medicine at the University of Pittsburgh School of Medicine, under the direction of Paul M. Paris, M.D., F.A.C.E.P., is one of the largest academic departments in the United States. Roughly 40,000 patients are treated each year. Department faculty are recognized authorities in many specialty areas of emergency medicine, including prehospital care, pain management, decision guidelines, airway management, toxicology, resuscitation medicine, disaster planning and injury prevention.

The ASPIRE Trial is funded through a grant from Revivant Corporation.

For more information about the public forums, or to make comments or ask questions about the ASPIRE Trial, researchers can be contacted at the following:

By Telephone:
Call the ASPIRE principal investigator at 412-647-2694.

By Mail:
University of Pittsburgh
Department of Emergency Medicine
230 McKee Place, Suite 911
Pittsburgh, Pa., 15213
Attention: Vincent N. Mosesso, M.D., principal investigator

By E-mail:
MosessoVN@upmc.edu

By Web:
http://www.pitt.edu/~aspire

http://clinicaltrials.gov/show/NCT00120965 

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com